- Conditions
- Renal Failure
- Interventions
- LCP Tacro (tacrolimus), Prograf
- Drug
- Lead sponsor
- Veloxis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 2
- States / cities
- Cincinnati, Ohio • Houston, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1681–1704
of 6,600
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Influenza
- Interventions
- Reverse Genetic (RG) reassortant A/H9N2 influenza vaccine
- Biological
- Lead sponsor
- Alachua Government Services, Inc.
- Industry
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 353 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2012
- U.S. locations
- 5
- States / cities
- Huntsville, Alabama • Melbourne, Florida • Peoria, Illinois + 2 more
- Conditions
- Cardiac Amyloidosis, AL Amyloidosis, ATTR Amyloidosis
- Interventions
- [18F]florbetaben
- Drug
- Lead sponsor
- Lantheus Germany GmbH
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 244 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 3
- States / cities
- Kansas City, Kansas • Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania
- Conditions
- Discogenic Pain
- Interventions
- High yield pure PRP, Placebo, ProPlaz PPC
- Device · Other
- Lead sponsor
- Neurological Associates of West Los Angeles
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 7
- States / cities
- Campbell, California • Santa Monica, California • Peachtree City, Georgia + 2 more
- Conditions
- Diabetes Mellitus, Diabetes Mellitus, Type 1, Glucose Metabolism Disorders, Endocrine System Diseases, Autoimmune Diseases
- Interventions
- FlorenceM, Medtronic insulin pump 640G
- Device
- Lead sponsor
- University of Cambridge
- Other
- Eligibility
- 6 Years and older
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 3
- States / cities
- Aurora, Colorado • Minneapolis, Minnesota
- Conditions
- Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
- Interventions
- Ipilimumab, Nivolumab
- Drug
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Acne Vulgaris
- Interventions
- SB204 2%, SB204 4%, Vehicle Gel
- Drug
- Lead sponsor
- Novan, Inc.
- Industry
- Eligibility
- 12 Years to 40 Years
- Enrollment
- 213 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 20
- States / cities
- Hot Springs, Arkansas • Encinitas, California • San Diego, California + 15 more
- Conditions
- Multiple Sclerosis (MS)
- Interventions
- Tecfidera, Placebo
- Drug
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 87 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 11
- States / cities
- Los Angeles, California • Baltimore, Maryland • Rochester, Minnesota + 7 more
- Conditions
- Biliary Tract Cancer
- Interventions
- Nivolumab, Nanoliposomal-Irinotecan, 5-Fluorouracil, Leucovorin
- Drug
- Lead sponsor
- University of Michigan Rogel Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 5
- States / cities
- Ann Arbor, Michigan • Grand Rapids, Michigan • Salt Lake City, Utah + 2 more
- Conditions
- Malaria, Malaria, Cerebral
- Interventions
- Intravenous Artesunate, Placebo
- Drug
- Lead sponsor
- U.S. Army Medical Research and Development Command
- Federal
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2008
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Renal Impairment
- Interventions
- RO7079901
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 29 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2017
- U.S. locations
- 5
- States / cities
- Miami, Florida • Orlando, Florida • Minneapolis, Minnesota + 2 more
- Conditions
- Migraine
- Interventions
- divalproex sodium
- Drug
- Lead sponsor
- Abbott
- Industry
- Eligibility
- 12 Years to 17 Years
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2003
- U.S. locations
- 1
- States / cities
- North Chicago, Illinois
- Conditions
- Depression
- Interventions
- ABP688
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 55 Years to 80 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2010
- U.S. locations
- 2
- States / cities
- New York, New York • Pittsburgh, Pennsylvania
- Conditions
- Locally Advanced Rectal Adenocarcinoma
- Interventions
- APX005M, mFOLFOX, and Radiation Therapy 5Gy x 5 days, mFOLFOX and Radiation Therapy 5Gy x 5 days
- Drug
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 4
- States / cities
- Tucson, Arizona • Winston-Salem, North Carolina • Portland, Oregon + 1 more
- Conditions
- Autoimmune Hepatitis
- Interventions
- LCP-Tacro (tacrolimus), Azathioprine
- Drug
- Lead sponsor
- Veloxis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 8
- States / cities
- Phoenix, Arizona • Jacksonville, Florida • Chicago, Illinois + 5 more
- Conditions
- Sleep Disorders
- Interventions
- Circadin 2/5/10 mg, Placebo
- Drug
- Lead sponsor
- Neurim Pharmaceuticals Ltd.
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 125 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 18
- States / cities
- Phoenix, Arizona • Miami Lakes, Florida • Orange City, Florida + 14 more
- Conditions
- Neurogenic Detrusor Overactivity
- Interventions
- Darifenacin
- Drug
- Lead sponsor
- Warner Chilcott
- Industry
- Eligibility
- 2 Years to 15 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2013
- U.S. locations
- 9
- States / cities
- San Diego, California • Boston, Massachusetts • Detroit, Michigan + 6 more
- Conditions
- Spinal Cord Injury
- Interventions
- CSFD and elevation of MAP, Maintenance of MAP
- Procedure
- Lead sponsor
- St. Joseph's Hospital and Medical Center, Phoenix
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 3
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona
- Conditions
- Type 2 Diabetes
- Interventions
- Not listed
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 4,500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2006
- U.S. locations
- 165
- States / cities
- Birmingham, Alabama • Columbiana, Alabama • Mobile, Alabama + 162 more
- Conditions
- Type 2 Diabetes
- Interventions
- ITCA 650, ITCA placebo
- Drug · Other
- Lead sponsor
- Intarcia Therapeutics
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 460 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 121
- States / cities
- Birmingham, Alabama • Gulf Shores, Alabama • Huntsville, Alabama + 102 more
- Conditions
- Invasive Fungal Infections
- Interventions
- SUBA itraconazole, Conventional itraconazole
- Drug
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 88 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 11
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Sacramento, California + 7 more
- Conditions
- Rheumatoid Arthritis
- Interventions
- Abatacept (ABA) + Methotrexate (MTX), double-blind (DB), Infliximab (INF) + MTX, DB, Placebo (PLA) + MTX, DB, PLA + MTX switched to ABA+ MTX, DB, ABA, open-label (OL)
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 431 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2009
- U.S. locations
- 19
- States / cities
- Huntsville, Alabama • Denver, Colorado • Boca Raton, Florida + 16 more
- Conditions
- Triple Negative Breast Cancer, Inflammatory Breast Cancer Stage IV
- Interventions
- Bemcentinib; pembrolizumab
- Drug
- Lead sponsor
- BerGenBio ASA
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 5
- States / cities
- Duarte, California • San Diego, California • Kansas City, Missouri + 2 more
- Conditions
- Congenital Bleeding Disorder, Haemophilia A, Haemophilia B
- Interventions
- eptacog alfa (activated), vatreptacog alfa (activated)
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 12 Years and older · Male only
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 12
- States / cities
- Los Angeles, California • Augusta, Georgia • Chicago, Illinois + 9 more